All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PF-05251749
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Biogen
Deal Size: $710.0 million Upfront Cash: $75.0 million
Deal Type: Acquisition January 13, 2020
Details:
With this purchase, Biogen plans to develop the Phase 1 asset for the treatment of Sundowning in Alzheimer’s disease (AD) and Irregular Sleep Wake Rhythm Disorder in Parkinson’s disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): YTX-7739
Therapeutic Area: Neurology Product Name: YTX-7739
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Yumanity Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger December 23, 2020
Details:
The combined company will operate under the name Yumanity Therapeutics. Yumanity’s lead product candidate is YTX-7739, which is currently in Phase 1 clinical development for the treatment and disease modification of Parkinson’s disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cannabinoids
Therapeutic Area: Neurology Product Name: IGC-AD1
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2020
Details:
IGC Pharma, LLC, received approval from an Institutional Review Board as previously disclosed, engaged a Principal Investigator and a study site, and began enrolling participants for a Phase 1 trial on its Investigational Drug Candidate, IGC-AD1.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EC5026
Therapeutic Area: Neurology Product Name: EC5026
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2020
Details:
No drug-related adverse events or changes in vital signs or clinical labs were observed, and the final clinical study report concludes that EC5026 is safe and well tolerated when given as a single oral dose ranging from 0.5 to 24 mg.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Glucarpidase,Methotrexate
Therapeutic Area: Neurology Product Name: Voraxaze
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2020
Details:
An ongoing arm of the study triggered by the difficult circumstances created by the COVID-19 pandemic is exploring the planned use of Voraxaze® (glucarpidase) to enable high dose MTX treatment of CNSL on an outpatient basis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LP352
Therapeutic Area: Neurology Product Name: LP352
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: Arena Pharmaceuticals
Deal Size: $56.0 million Upfront Cash: Undisclosed
Deal Type: Financing October 28, 2020
Details:
Proceeds from the financing will be used to support the development of LP352 for treatment-resistant developmental and epileptic encephalopathies, and preclinical programs relating to LP143 and LP659 for the potential treatment of microglial neuroinflammatory diseases.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Leronlimab
Therapeutic Area: Neurology Product Name: PRO 140
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
Company is accelerating the filing of a Ph2 protocol to evaluate leronlimab’s potential as a therapeutic for stroke recovery. Administration of leronlimab resulted in approx. 70-75% CCR5 receptor occupancy in the Brain.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
